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Abstract
Objective: The objective of this selective EBM review is to
determine whether or not the use of oral amphetamines
reduces cocaine use in cocaine-dependent individuals.
Study Design: Review of three English language randomized
control trials (RCTs) published in 2001, 2003 and 2004.
Data Sources: 3 randomized controlled trials published
after 1999 were obtained using PubMed, OVID, and Medline.
Outcomes Measured: The efficacy of using d-amphetamine to
promote cocaine use cessation in cocaine-dependent
individuals, determined using immunoassay and mass
spectrometric analysis to identify cocaine metabolites in
the participant’s urine.
Results: Grabowski et al (2004) found a significant
reduction in the use of cocaine in cocaine-dependent
individuals, while Grabowski et al (2001) and Shearer et al
were unable to show a significant reduction.
Conclusion: Evidence supporting the role of oral
amphetamines in reducing cocaine use in cocaine-dependent
individuals is inconclusive and conflicting at this time.
However, further research and larger scale analysis is
warranted and feasible considering the suggestive outcomes
these studies represent.
Keywords: Cocaine-dependence, d-amphetamine, randomizedcontrolled trial, treatment
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Introduction
Cocaine is a drug with increasing concern for abuse
and dependence, with minimal available treatment options,
that is in association with an array of psychiatric,
medical, and individual social problems1. The drug is coined
“the caviar of street drugs,” and given a reputation to be
abused by celebrities, fashion models, and Wall Street
traders2. However, addiction is a disease that does not
discriminate, affecting individuals of all backgrounds and
socioeconomic status. The effects of cocaine not only occur
during the “high”, which only lasts about 15 minutes, but
afterwards the negative effects take a toll on the heart,
brain, and one’s emotions2. Considering the long-term damage
consuming this drug has on the body, it is imperative to
determine a way to help cocaine-dependent individuals
overcome their addiction. This paper evaluates three double
blind, randomized controlled trials determining the
efficacy of Amphetamine (d-amphetamine) as an oral
medication to promote cessation of cocaine use.
There are approximately 1.6 million current users of
cocaine in the US, with the past-year prevalence of cocaine
dependence is estimated to be 1.1%3. With such a high rate
of addiction, it is alarming to consider the strain it has
on our country’s health care expenses. Although an
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estimation of annual healthcare cost due to cocainedependence is not recorded, it is included in the more than
$484 billion dollars that substance abuse as a whole costs
our nation per year, as reported by the National Institute
of Drug Abuse4. Health care practitioners are exposed to a
large number of these patients on a daily basis.
Considering some people keep it hidden that they are
abusing drugs, it is difficult to accurately depict. There
is not an exact estimate available for healthcare visits
due to cocaine-dependence; however, in 2009 NIDA reported
an estimated 422,896 emergency room visits related to
cocaine use5.
Cocaine addiction/dependence is proven to be in
association with the stimulatory effect the drug has on the
central nervous system’s reward inducing center6. The
sympathomimetic mechanism of action directly increases the
activation of dopaminergic receptors, while also blocking
the reuptake of norepinephrine and serotonin6. CNS
stimulation from cocaine use has shown to increase harmful
behavior in addicted individuals.

These behaviors include

psychosis, HIV and other transmittable disease risk-taking
through unsafe sexual practice and injecting, compulsive
binge behavior, violence, and other antisocial behaviors6.
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The drug effects can even change one’s personality enough
to alter their actions.
Stimulatory drugs, which are controlled substances,
are the only class of medications that are showing promise
as therapeutic agents for treatment of cocaine dependence.
However, there is resistance in this field of research
considering the addictive properties of these
pharmaceutical medications6. Research and treatment are
being conducted in other countries using other stimulant
medications such as: Dopamine agonists, Methylphenidate,
Modafinil, Armodafinil, and stimulant antidepressants such
as Bupropion3. Cognitive-behavioral psychosocial therapy is
also an adjunctive mainstay of treatment for cocaine
dependence7. Currently there is not a drug of choice for
promoting cessation of cocaine use in patients with
cocaine-dependence.

The medications previously listed have

shown minimal efficacy in controlled studies. Research
suggests that d-amphetamine may be used as an oral
alternative to treat patients with cocaine-dependence with
the goal to improve the likelihood of cessation.
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Objective
The objective of this selective EBM review is to
determine whether or not the use of oral amphetamines can
reduce cocaine use in cocaine-dependent individuals.
Methods
The criteria used for selection of the studies used
were patients with cocaine-dependence who were seeking help
in cessation of use and who were willing to participate in
a controlled research trial. The intervention used was damphetamine 30mg and 60mg daily. The treatment group
receiving d-amphetamine was compared to the control group
who was receiving a visually matched placebo. The outcome
measured was the efficacy of using d-amphetamine to promote
cocaine use cessation in cocaine-dependent individuals.
This was determined using immunoassay and mass
spectrometric analysis to identify cocaine metabolites in
the participant’s urine. The types of studies included were
3 randomized, double blind, and placebo controlled clinical
trials.
The data sources used are 3 randomized controlled
trials published after 1999 that were obtained using PubMed,
OVID, and Medline. The keywords used in searches were
“Cocaine-dependence”, “d-amphetamine”, “randomized-
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controlled trial”, and “treatment”. All of the articles
were written in English and published in peer-reviewed
journals.

The articles were selected based on their

relevance to the clinical question and if they included
patient oriented outcomes. The inclusion criteria involved
were studies that were randomized, controlled, and double
blind. The participants in the trials were cocainedependent, without an age requirement. The exclusion
criteria in the RCTs were patients with medical
comorbidities that could interfere with the study outcomes.
All the studies utilized in this review deal with patient
oriented outcomes (POEMS). The summary statistical analysis
utilized in the studies reviewed included ANOVA, NNT, ABI,
p-values, and F-score. Table 1 demonstrates the
demographics of the participants in the study.
Outcome Measured
The outcome measured was the efficacy of using damphetamine to promote cocaine use cessation in cocainedependent individuals. This was determined by the absence
of cocaine metabolites in that participant’s urine. A
urinalysis was conducted using laboratory immunoassay and
mass spectrometry to identify benzoylecgonine, a metabolite
of cocaine, at a cutoff of 300ng/mL.
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Table 1: Demographics and Characteristics of included studies
Study

Grabowski8
(2004)

Grabowski7
(2001)

Shearer6
(2003)

Type

Double
blind
RCT

Double
blind
RCT

Double
blind
RCT

# of
Pts.

94

128

30

Age (yrs)

Inclusion
Criteria

Exclusion
Criteria

18-50

Cocaine
and heroin
dependence
diagnosis
(DSM IV)
in good
health and
without
other
psych
diagnosis
with
normal
cardiac
function

Other
significant
medical
diagnosis

Not
Specified

Cocainedependence
diagnosis
(DSM IV)
in good
medical
health

Other
psychiatric
diagnosis

Not
Specified

Cocaine
dependence
diagnosis
(DSM-IV
criteria)
and a
cocainepositive
urine
sample or
documented
history of
cocaine
use

Other
significant
medical
conditions
likely to make
trial
participation
hazardous (such
as
cardiovascular
conditions and
schizophrenia).

W/D

Interventions

32

15/30mg and
30/60mg of damphetamine
per day and
methadone
x 26 weeks

16

15/30mg and
30/60mg of damphetamine
x 12 weeks

4

60mg of damphetamine
per day
x 14 weeks
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Results
Three studies were included, two of which compared damphetamine therapy group against placebo group in cocainedependent individuals, and one that compared d-amphetamine
therapy group against placebo group in cocaine and heroindependent individuals. Two of the studies did not specify
an age parameter, but the third study restricted it to 18
to 50 years of age. To report conclusive data, individuals
were presumptive for cocaine use if their benzoylecgonine
(BZ) level was 300 ng/mL or greater on urine screening.
In the study by Grabowski et al (2001), three groups
were analyzed. There was a group taking 0mg (placebo),
15/30mg d-amphetamine, and 30/60mg d-amphetamine. The trial
was 12 weeks in duration and included 128 individuals. The
proportion of urine screens that were positive at intake
was 0.80, 0.68, and 0.65, respectively, for the individuals
designated to each group previously listed. There was a
dose-doubling phase that occurred at month two. For the
complete sample, differences were not significant at the
end of the study (Pearson x2=2.257, df=2,p=0.323, N=128).
When examining if there was a difference with dose as a
variable, there still was no significance (F=0.147,
df=2.99,p=0.864,N=102). However, all groups showed
improvement. When the 16 individuals with negative urine
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drug screen from initial screening (entry of study) who
continued to be negative throughout the study were excluded,
there was a difference in the pattern of cocaine use. The
data for month 1 was similar to the complete sample, but
differences emerged after the dose was doubled. The 60mg
group showed fewer BZ-positive urine screens than placebo
group during month 3 (F=4.577, df=1.9, p=0.061, N=11), but
this data was not significant. The study reported six
subjects that stated medication side effects as a reason
for discontinuation of therapy. These included changes in
their appetite and muscle twitches or movements. The study
concludes that there was an absence of adverse effects that
diminishes concerns for this treatment, but caution is
essential7.
In the study Grabowski et al (2004), three groups were
involved in the study, 0mg, 15/30mg, and 30/60mg of damphetamine. Of the 94 subjects who began the medical
treatment, 62 remained at the end of the study. This study
also included a dose-doubling phase at month two. Analysis
comparing the single to doubled dose phases indicated that
the 30/60-dose group significantly reduced cocaine use when
compared to the other groups (Interaction F=4.34, df=2.56,
p=0.0176; Cohen’s effect-size f=0.394). The side effects
noted were changes in appetite, constipation, and

Strate, Oral Amphetamine in Cocaine-Dependent 9
drowsiness, leading to only a 2% dropout rate. The safety
concern was of cardiovascular origin, requiring each
subject to be evaluated by a cardiologist prior to
initiation of therapy8.
In the study Shearer et al, the 30 subjects were
cocaine and heroin-dependent and were divided into two
groups, 0mg (placebo) or 60mg d-amphetamine. The proportion
of positive urine samples declined in the treatment group
from 94% at baseline to 56% and 69% during the study. The
placebo group’s positive urine samples remained constant at
79% throughout the study. The between-group difference at
the final week 14 was 22.4% (x2=1.7, p=0.2), not showing
significant difference. As calculated by the results of the
study, for every 10 subjects treated with oral amphetamines,
one more would discontinue cocaine use when compared to
placebo (NNT represented in Table 2). The commonly reported
side effects during this study were insomnia and disturbed
sleep, however they did not differ between groups6.
Table 2: Clinical Efficacy of Using d-amphetamine to treat Cocaine-Dependence

Study

CER (0mg)

EER (60mg)

ABI

NNT

Shearer et al

21%

31%

10%

10

CER- control event rate, EER- experimental event rate, ABI- absolute benefit increase,
NNT- number needed to treat
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Discussion
Although all trials do not show significant evidence,
they imply that d-amphetamine at higher doses (60mg) could
be a potentially safe and effective treatment to reduce
cocaine use in cocaine-dependent individuals. However, the
possibility of adverse events may lead to skepticism.
Insurance companies currently cover the cost of damphetamine for most individuals for the treatment of
attention deficit disorder. However, it has not been
approved for this application. Considering the fact that
this medication is CNS stimulating in nature, there is also
potential for abuse.
The study by Shearer et al was too small to
confidently evaluate the efficacy of d-amphetamine in
relation to placebo in reducing cocaine use, cravings and
related harms6. The size of the study is a limiting factor
in this field of research. Grabowski et al (2004) found a
significant reduction in the use of cocaine in cocainedependent individuals, while Grabowski et al (2001) and
Shearer et al were unable to show a significant reduction.
Furthermore, as a whole, these studies give support to
merit future controlled studies to evaluate the utility of
d-amphetamine in the management of cocaine dependence.
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Conclusion
Evidence supporting the role of oral amphetamines in
reducing cocaine use in cocaine-dependent individuals is
inconclusive and conflicting at this time. Nevertheless,
further research and larger scale analysis is warranted and
feasible considering the suggestive outcomes these studies
represent.
Future studies should attempt to increase the amount
of participants and put particular emphasis on patients
with cocaine-dependence alone, instead of subjects with
multiple drug dependencies. Higher dosing at 60mg daily damphetamine appears to be the more promising treatment.
Focus on comparing placebo to the higher dose in a
controlled setting could show more profound statistical
outcomes. Also, the duration of the studies should be
lengthened to prove safety of this treatment for long-term
control. Although the results of these studies are modest,
treatment with d-amphetamine shows more promising outcomes
than other previously researched medications in treating
the serious problem of cocaine-dependence and abuse.

References
1

Nuijten M, Blanken P, van den Brink W, Hendriks V. Cocaine
addiction treatments to improve control and reduce harm
(CATCH): New pharmacological treatment options for crackcocaine dependence in the netherlands. BMC Psychiatry
2011;11:135-244.
2

Cocaine Use and Its Effects: WebMD.
http://www.webmd.com/mental-health/addiction/cocaine-useand-its-effects. Accessed November 20, 2015.
3

Mariani JJ and Levin FR. Psychostimulant treatment of
cocaine dependence. Psychiatr Clin North Am. 2012; 35(2):
425–439.
4

Rice DP. Economic Costs of Substance Abuse, 1995. Proc
Assoc Am Phys 111(2): 119-125, 1999.
5

National Institute on Drug Abuse; National Institutes of
Health; U.S. Department of Health and Human Services.
Website. http://www.drugabuse.gov. Accessed October 7, 2015.
6

Shearer J, Wodak A, van Beek I, Mattick RP, Lewis J. Pilot
randomized double blind placebo-controlled study of
dexamphetamine for cocaine dependence. Addiction (Abingdon,
England) 2003;98(8):1137-1141.
7

Grabowski J, Rhoades H, Schmitz J, Stotts A, Daruzska LA,
Creson D, et al. Dextroamphetamine for cocaine-dependence
treatment: A double-blind randomized clinical trial.
Journal of Clinical Psychopharmacology 2001;21(5):522-526.
8

Grabowski J, Rhoades H, Stotts A, et al. Agonist-like or
antagonist-like treatment for cocaine dependence with
methadone for heroin dependence: two double-blind
randomized clinical trials. Neuropsychopharmacology
2004;29(5):969–81.

